Rafferty brings to BioSig over 30 years of leadership experience with traditional corporate and emerging growth companies. Having functioned as CEO, general manager, vice president of global sales and marketing, vice president of physician training, vice president of sales training, and director for national contracts, Rafferty has created a legacy of building and leading teams with industry leaders like Pathway Medical, Avinger, ACS/Guidant, C.R. Bard Vascular/Cardiovascular, Synthes Spine, Sterilox, J&J’s Ethicon Mechanical Products (Endo) and, most recently, as CEO of National Medical Sales LLC.
While at ACS/Guidant, Rafferty authored and implemented the “P3," or price per procedure model for interventional cardiology. The P3 model has leveraged ACS's full line of products, creating a significant barrier to competitors and visibility to expenses for providers negotiating with payors. Driving hundreds of millions of dollars in revenue, the "P3" quickly became the model for how business is conducted in the multi-billion dollar interventional cardiovascular sector. The "P3" has since been adopted by many other subspecialty markets.
'“Timing is everything in life,' is a quote my parents often repeated,” Rafferty said. “I feel very fortunate to be asked to join the BioSig team and lead the global commercialization efforts at this critical juncture. Bioelectronic Medicine is a quickly emerging market. The BioSig technology has a true platform capability to be leveraged in many bioelectronic medical applications.”
Kenneth Londoner, CEO and chairman of BioSig Technologies, added, “Commercial launch is one of the most important steps for any medical technology company. Prior to onboarding Joe, we did five months of two-way due diligence on one another, as this position is a critical one for BioSig. We had to make the right choice. Joe has demonstrated to our board that he has the skills, the experience, and, most importantly, the track-record to successfully launch the PURE EP System. We look forward to working with Joe and his agile A-team on building our commercial capabilities. We are on track for a targeted launch in the second half of 2018.”
BioSig Technologies is a medical device company developing a proprietary technology platform designed to improve the $4.6 billion electrophysiology (EP) marketplace. Led by a management team and a veteran, independent Board of Directors, Minneapolis, Minn.-based BioSig Technologies is preparing to commercialize its PURE EP(TM) System. The technology has been developed to address an unmet need in a large and growing market. The PURE EP System is a novel cardiac signal acquisition and display system which is engineered to assist electrophysiologists in clinical decision making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig’s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. BioSig has partnered with Minnetronix on technology development and is working toward U.S. Food and Drug Administration 510(k) clearance for the PURE EP System.